Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

Comment by thathurton Nov 25, 2015 3:02pm
82 Views
Post# 24325291

RE:RE:RE:The 88/12 rule

RE:RE:RE:The 88/12 rule
tson, again another silly attack on this board when you posted this:

<<Weren't all of the patients in the trial deemed non-responsive to BCG????? How can you or the panel then question wheter it was MCNA or BCG that was providing the benefit? The whole point of the trial and the BLA is to help people that are non-responsive to BCG.>>

it wasn't me questioning that it was the panel and in fact the FDA questioning whether the effect was due to MCNA...i believe one question was related to "BCG priming MCNA" and FYI one of the members stated i believe that he only attributed 3 responses in 93 patients as unequivacable MCNA responses, this was/is a question, whether we believe or not.
<< Previous
Bullboard Posts
Next >>